Latest Regulatory Clearance News

Global Uranium and Snow Lake Resources have agreed to merge, creating a leading U.S.-focused uranium company valued at A$44.5 million. The deal consolidates key assets and promises enhanced exploration and development opportunities.

The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.

Orthocell has reported a record $3 million revenue for the September quarter, driven by strong sales of its nerve repair product Remplir™ in Australia and Singapore, with early US sales and Canadian market entry poised to accelerate growth.

Savannah Goldfields is on track to resume gold production at its Georgetown Gold Project by the end of October, with key maintenance and environmental approvals completed.

Seven West Media and Southern Cross Media have announced a proposed all-scrip merger to create a leading integrated media company spanning TV, audio, digital, and publishing platforms across Australia.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

Hastings Technology Metals has signed a binding agreement to sell its gold assets to Metal Bank Limited in a share-and-cash deal, marking a strategic pivot towards rare earths and niobium development.

Race Oncology has secured Investigational New Drug approval from South Korea’s regulatory authority, enabling Phase 1 clinical trials of RC220 in combination with doxorubicin for solid tumour patients across four Korean sites.

Amplitude Energy is expanding its East Coast Supply Project by adding a fourth well at the Nestor prospect and plans a potential restart of the Patricia Baleen field, supported by a $150 million equity raising to fund these growth initiatives.

Shriro Holdings has reversed its plan to delist from the ASX and scrap a $5 million share buy-back, now considering a special dividend to reward shareholders.

Peak Rare Earths has postponed its critical court hearing for Shenghe Resources' acquisition scheme due to a delay in Tanzanian regulatory approval, pushing the decision to 19 September 2025.

Imricor Medical Systems has successfully completed a comprehensive Human Factors study for all its devices under FDA review, marking a critical milestone towards U.S. market entry. The extensive 7-month study involved 46 healthcare professionals and tested nine products, underscoring Imricor’s growing momentum in electrophysiology innovation.